|View printer-friendly version|
|June 27, 2017 8:16 a.m.|
|Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint|
This was a Phase II proof of concept study seeking to understand the
potential for a topical route of Nav1.7 blockade in PHN. Dr.
The companies plan to further analyze the data from this study to determine the next steps for TV-45070, and may look to present study data at a relevant forthcoming scientific conference.
TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7, and
other sodium channels, expressed in the pain-sensing peripheral nervous
system. TV-45070 was licensed by Xenon to Teva in
This Phase II trial was a randomized, double-blind, placebo controlled, parallel group, multicenter study to evaluate the efficacy and safety of TV-45070 in patients with PHN. The study included three treatment groups that received topical ointment containing 4% or 8% TV-45070 or placebo, dosed twice daily. The primary endpoint of this study was the change of average daily pain scores from baseline to week four, measured using an 11-point (0-10) numeric rating scale (NRS).
Secondary endpoints included the percentage of patients with greater than 30% and greater than 50% improvement in pain scores, quality of life measurements and adverse events measurements. The study was carried out at 48 centers in the US and involved 300 patients randomized to 100 patients receiving 4% TV-45070, 100 patients receiving 8% TV-45070 and 100 patients receiving placebo.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy. For more information, please visit www.xenon-pharma.com.
Teva Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding TV-45070 which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 (“Annual Report”), including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Xenon’s Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. These
forward-looking statements are not based on historical fact, and include
statements regarding the anticipated timing of IND submissions with
regulatory agencies, the initiation of future clinical trials, the
future development plans for TV-45070 and the progress and potential of
ongoing development programs. These forward-looking statements are based
on current assumptions that involve risks, uncertainties and other
factors that may cause the actual results, events or developments to be
materially different from those expressed or implied by such
forward-looking statements. These risks and uncertainties, many of which
are beyond our control, include, but are not limited to: clinical trials
may not demonstrate safety and efficacy of any of our or our
collaborators' product candidates; our discovery platform or ongoing
collaborations may not yield additional product candidates; our efforts
to expand our current pipeline may not be successful; any of our or our
collaborators' product candidates may fail in development, may not
receive required regulatory approvals, or may be delayed to a point
where they are not commercially viable; we may not achieve additional
milestones pursuant to our collaboration agreements; the impact of
competition; the impact of expanded product development and clinical
activities on operating expenses; adverse conditions in the general
domestic and global economic markets; as well as the other risks
identified in our filings with the
“Xenon” and the Xenon logo are registered trademarks or trademarks of